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Abstract. The effectiveness of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine
(IPTp-SP) against malaria and anemia is unclear because of the spread of SP-resistant Plasmodium falciparum. This
study evaluates the effectiveness of IPTp-SP among pregnant women attending the antenatal clinic at Korle-Bu Teaching
Hospital in Accra, Ghana. A cross-sectional study comparing malaria and anemia prevalence among pregnant women
using IPTp-SP with non-IPTp-SP users was conducted during June–August 2009. A total of 363 pregnant women (202 of
IPTp users and 161 non-IPTp users) were recruited. A total of 15.3% of IPTp users had malaria compared with 44.7%
of non-IPTp users (P < 0.001). A total of 58.4% of non-IPTp users were anemic compared with 22.8% of IPTp users
(P < 0.001). When we controlled for other variables, the difference in the prevalence of malaria (odds ratio = 0.18, 95%
confidence interval = 0.08–0.37) and anemia (odds ratio = 0.20, 95% confidence interval = 0.12–0.34) remained significant.
The recommended IPTp-SP regimen is useful in preventing malaria and anemia among pregnant women in Ghana.

compliance, high cost, and impairment of natural immunity
to malaria.10 The previous anti-malarial drug policy in Ghana
promoted chloroquine chemoprophylaxis during pregnancy
and six weeks post-partum.11 However, compliance was low
(11.6%).9 This low compliance rate reduced effectiveness of
malaria prevention among this group.9
As a result, Ghana adopted the current World Health
Organization (WHO) recommended standard of care for
malaria in malaria-endemic regions, which is intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP).13 IPTp-SP has been shown to
reduce malaria episodes, malaria-related anemia, and incidence of LBW.14–17 In addition, IPTp-SP is attractive because
of its single-dose therapy, which lends itself to supervised
administration and ensures compliance.
Although this preventive strategy has been implemented in
some hospitals in Ghana such as Korle-Bu Teaching Hospital
(KBTH), there has been little assessment of its effectiveness
in preventing maternal malaria and malaria-associated anemia in Africa.18 In addition, resistance to SP is increasing in
West Africa and thus the effectiveness of IPTp-SP has been
questioned.19,20 Furthermore, SP treatment failure has been
observed in 36% of children and approximately 30% of
pregnant women in central Ghana.21 Nevertheless, the frequency of the dihydrofolate reductase triple mutation among
Plasmodium falciparum isolates, which confers resistance to SP
has been observed in 73% of pregnant women in other parts
of the country.22 However, recent meta-analysis indicated no
marked decrease in the efficacy of the IPTp regimen among
women in areas with treatment-failure rates of 3–39% among
children.23 Examining possible correlation between IPTp-SP
use and decreased prevalence of maternal malaria and malariaassociated anemia despite increased resistance may provide
insight into its effectiveness in controlling malaria and anemia in pregnancy. In this study, the effectiveness of IPTp-SP in
preventing maternal malaria and malaria-associated anemia
among pregnant women attending antenatal clinic (ANC) at
KBTH was assessed.

INTRODUCTION
An estimated 243 million cases of malaria occurred in 2008
globally, most of which were reported in sub-Saharan African
children less than five years of age and resulted in 863,000
deaths.1 Malaria in pregnancy is an immense public health
problem that affects approximately 50 million women per
year in malaria-endemic areas.2 Pregnant women, especially
primigravidae and secundigravidae, are particularly vulnerable to malaria than non-pregnant women from the same
area.3 Maternal anemia and low birth weight babies (LBW)
are two important consequences of malaria in pregnancy.4
The etiology of anemia in pregnancy is often multi-factorial
with causes ranging from nutritional deficiency of iron,
folate, vitamin A or other nutrients, hemoglobinopathies
(sickle cell disease), and infection with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/
AIDS) or parasites, such as hookworm and Plasmodium.5–7
However, in sub-Saharan Africa, malaria is a major contributory cause of anemia, especially among primigravidae living in holoendemic areas or perennially exposed to malaria.6
Malaria-associated anemia puts pregnant women at greater
risk of other morbidities including placental abruption,
placenta previa, premature labor, and maternal death.8 In
addition, LBW babies are at an increased risk for early childhood mortality.
In Ghana, among pregnant women, malaria accounts for
13.8% of outpatient department (OPD) attendance, 10.6% of
admissions, and 9.4% of deaths.9 Malaria prevention in pregnancy with chemoprophylaxis is associated with reduced incidence of malaria episodes, higher mean maternal hemoglobin
levels, and reduced incidence of LBW babies.10–12 However,
chemoprophylaxis has some potential drawbacks such as poor
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MATERIALS AND METHODS
Study area and population. This study was conducted at
KBTH, which is located in Accra, Ghana. The hospital, which
is the leading teaching hospital in Ghana, serves as the ultimate referral institution for patients from diverse population
all over the country and functions as the premier teaching
hospital for the Ghana Medical School. Malaria is the number
one cause of morbidity in the country, accounting for approximately 38% of all OPD attendance, 36% of all admissions,
and 33.4% of all mortality in children less than five years of
age.24 The groups affected most by malaria in the country are
children less than five years of age and pregnant women, who
constitute 20% and 4%, respectively, of the general population.25 The current study determined whether pregnant women
attending prenatal clinic at KBTH who have taken IPTp-SP
have low prevalence of malaria and malaria-related anemia
compared with those who have not used the IPTp.
Recruitment of participants. The study was designed to
assess the effectiveness of IPTp-SP in pregnant women attending the ANC at KBTH during June–August 2009. The pregnant women were recruited into the study from the prenatal
outpatient clinic based in the KBTH after providing informed
consent according to the standards of Morehouse School of
Medicine’s Institutional Review Board and the Ghana Health
Service ethical review committee. The selection criteria for
recruitment included pregnant women with a gestational age
of ≥ 26 weeks (third trimester), ≥ 18 years of age, who have
received at least one dose of IPTp-SP during the first two
trimesters of the pregnancy. Women with severe pregnancy
complications such as hemorrhages, sepsis, and infections
other than malaria, as well as women taking malaria prophylaxis other than IPTp-SP during the first two trimesters,
were excluded. The women were categorized based on use of
IPTp-SP before visiting the clinic.
Data collection methods. The women were screened for
malaria by microscopic evaluation of thick blood films stained
with Giemsa and classified as either positive or negative for
malaria. Because the reliability of Giemsa-stained thick blood
films depends on the quality of laboratory preparation, staining, and examining techniques, at least 10 fields were read
from each slide and three independent or separate microscopists were selected to review each slide to enhance accuracy
and prevent errors. Discordant results were excluded from
the study. Hemoglobin (Hb) levels of each participant were
determined by using the Sysmex KX-21 Hematology Analyzer
(Sysmex Corporation, Kobe Japan), and the numerical values
were recorded. The participants were also classified according
to their Hb levels as anemic (Hb < 11.0 g/dL), severely anemic
(Hb < 7.0 g/dL), and non-anemic (Hb > 11.0 g/dL) according
to WHO recommendations.2,26
Information was obtained by using an interviewer-administered structured questionnaire written in English that was
administered by two local interviewers and one of the principal investigators in the language the respondents understood
better. The questionnaire comprised of questions on sociodemographic characteristics, obstetric history, IPTp use, knowledge of malaria and anemia prevention, and food or folate
supplement to determine the effect of these factors on malaria
and anemia. The participants were also asked the type of preventive measures or methods they use against malaria. The
HIV, sickle cell, glucose-6-phosphate dehydrogenase (G6PD)
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deficiency status, IPTp use of the participants, and helminth
infections were determined by reviewing their antenatal cards
or records. In terms of education, the women were classified
as primary where they have completed ≤ 9 years of education,
secondary where they had completed senior secondary school
comprising 10–12 years of education, and tertiary where participants had completed university education or higher (≥ 13
years).
Statistical analysis. All data entry, management, and basic
statistics were conducted using SPSS statistical software version 17.0 for Windows (SPSS Inc., Chicago, IL) and transferred to Stata version 9.2 (Stata Corp., College Station, TX)
for logistic regression analysis. The basic demographic factors,
chart extraction characteristics, effect of IPTp-SP and malaria
prevention method on malaria, and effect of IPTp-SP and anemia prevention knowledge on anemia among the women were
compared for differences by using the Pearson chi-square test
and adjusting for the Yates correction for continuity where
appropriate. For instances in which there were too few persons
per cell for the Pearson chi-square test to be used, Fisher exact
test was used to compare discrete outcomes. One-way analysis
of variance on ranks was used to determine the significance
of the difference in anemia and severe anemia among IPTp
users and non-IPTp users. Associations between the outcome
variables, malaria and different categories of anemia, were
determined by using bivariate analysis. To assess the effect of
IPTp-SP on malaria and malaria-associated anemia, we constructed a logistic regression model and controlled for possible
confounding effects such as age, parity, gravidity, level of education, sickle cell status, G6PD, HIV status, helminth infection,
employment, marital status, family size, anemia prevention
knowledge, and malaria prevention method used. The model
fit was assessed for robustness by using the log-likelihood ratio
test and model estimates were compared at P < 0.001. In the
logistic regression model, age, parity, marital status, and family
size were treated as covariate and other variables were treated
as categorical variables. The odds ratio (OR) and 95% confidence interval (CI) were obtained by using logistic regression in multivariate analyses. In addition, the OR for malaria
and malaria-related anemia was calculated for women using
IPTp-SP and those who were not using IPTp-SP. Statistical significance was set at P ≤ 0.05.
RESULTS
Study population. A total of 381 women, which represented
approximately 23% of the total women attending the ANC
during June–August 2009 were recruited and 18 were excluded
from the study because of incomplete questionnaire or data.
A total of 363 women with complete questionnaires participated in the study analysis. The mean age of all women was
33.2 years (range = 18–48 years). There was a significant difference in mean age of the women using IPTp-SP (33.8 years)
and those not using IPTp, (32.4 years; P = 0.013). Most women
in the study had had a primary education, and more women
using IPTp had attained secondary level education (31.7%
versus 29.8%) and tertiary level education (25.7% versus
6.8%), a factor that may influence health-seeking behavior
(Table 1). Approximately 90% of the women were employed;
however, 70.5% of the women were in the low-income category (Table 1). Most women not using IPTp (80.1%) were in
the low-income category compared with 62.9% of those using
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IPTp (P < 0.001) (Table 1). Eighty-seven percent of the IPTp
users had a family size ≤ 4 persons compared with 83.2% nonIPTp users (P = 0.371) (Table 1).
Data from medical records or antenatal cards showed that
342 (94.2%) of 363 women were in their third trimester and
approximately 43% were primigravidae or secundigravidae
(Table 2). Most of the women had normal G6PD and were
negative for sickle cell status (93.1% and 90.3%, respectively).
Most (334, 92.0%) of the women were negative for HIV
and approximately 341 (94%) had no helminth infections.
However, 8 (4%) of 202 women using IPTp had roundworm
infections compared with 4 (3%) of 161 women not using IPTp
(P = 0.032) (Table 2). Helminth co-infection with malaria was
observed in 5 (3.1%) of 161 women not using IPTp (Table 2).
There were no statistically significant differences between the
two groups in terms of their marital status, gestation, gravidity, parity, family size, sickle cell status, G6PD status, and HIV
status (P > 0.05).
Effect of IPTp on malaria. Thick blood smears were prepared from all the 363 women at recruitment. One hundred
three (28.4%) women were positive for malaria parasites: 31
(15.3%) of 202 using IPTp and 72 (44.7%) of 161 not using
IPTp (P < 0.001). The effect of the use of malaria prevention
method (insecticide-treated nets [ITNs] or indoor residual
spraying [IRS]) on malaria among the women was determined
by asking the participant what preventive method they use.
There was no significant difference in ITN use among the
IPTp users (7.0%, 14 of 202) and non-IPTp users (5.6%, 9 of
161) (P = 0.657) (Table 3). However, 13.4% of IPTp users not

Table 1
Socio-demographic characteristics of pregnant women receiving antenatal care at Korle-Bu Teaching Hospital, Accra, Ghana, June–
August 2009*
Socio-demographic
characteristic

Age (years)
Mean ± SD
18–24
25–29
30–34
≥ 35
Marital status
Single
Married
Education
No education
Primary
Secondary
Tertiary
Employment grade
Professional
Clerical
Skilled
Unskilled
Unemployed
Socioeconomic status
Low income
Middle income
Family size
≤4
>4

IPTp-SP users
(n = 202)

Non-IPTp-SP users
(n = 161)

P

33.8 ± 5.2
4 (1.9%)
46 (22.8%)
46 (22.8%)
106 (52.5%)

32.4 ± 5.8
13 (8.1%)
46 (28.6%)
36 (22.4%)
66 (40.9%)

0.013
0.013

5 (2.5%)
197 (97.5%)

7 (4.3%)
154 (95.7%)

0.486

29 (14.4%)
57 (28.2%)
64 (31.7%)
52 (25.7%)

41 (25.5%)
61 (37.9%)
48 (29.8%)
11 (6.8%)

< 0.001

28 (13.9%)
59 (29.2%)
68 (33.7%)
45 (22.3%)
2 (0.9%)

10 (6.2%)
35 (21.7%)
57 (35.4%)
51 (31.7%)
8 (5.0%)

0.004

127 (62.9%)
75 (37.1%)

129 (80.1%)
32 (19.9%)

< 0.001

176 (87.1%)
26 (12.9%)

134 (83.2%)
27 (16.8%)

0.371

* IPTp-SP = intermittent preventive treatment with sulfadoxine-pyrimethamine; SD = standard deviation. Pearson chi-square test adjusting for the Yates correction for continuity where
appropriate was used to compare for statistical differences among the pregnant women. For
instances in which there were too few persons per cell for the Pearson chi-square test to be
used, Fisher exact test was used to compare discrete outcomes. Differences between group
means were assessed by using analysis of variance. Statistical significance was set at P ≤ 0.05.

using ITNs had malaria compared with 42.2% of non-IPTp
users not using ITNs (P < 0.0001) (Table 3). In addition, 6.4%
of IPTp users not using IRS had malaria compared with 20.5%
of non-IPTp users not using IRS (P < 0.0001) (Table 3).
Logistic regression analysis was used to assess the effect of
IPTp on malaria infection. The effect of age, gestation, marital
status, parity, and other variables was controlled. Data indicate that after controlling for possible confounding factors,
the statistically significant difference in the effect of the IPTp
in preventing malaria in pregnancy still remained (P < 0.001).
However, only the study status (i.e., IPTp use) and educational
status were shown to be statistically significant as an explanatory variable for malaria in pregnancy (Table 4). The chance
of malaria infection among pregnant women using IPTp was
18% that of women not using IPTp during pregnancy (OR =
0.18, 95% CI = 0.08–0.37, P < 0.0001). The chance of malaria
infection among educated (secondary or tertiary) pregnant
women with at least secondary education was 48% that of
women with no education (OR = 0.48, 95% CI = 0.28–0.81,
P < 0.006) (Table 4).
Effect of IPTp on anemia. Blood samples for Hb analyses were obtained from 363 pregnant women at recruitment.
Women using IPTp had significantly higher mean Hb levels
(11.6 g/dL) than women not using IPTp (9.8 g/dL) (P < 0.001)
(Table 5). The Hb level ranged from 6.1 to 14.8 g/dL for
IPTp users and from 5.0 to 13.0 g/dL for non-IPTp users
(Figure 1). The proportion of anemic women not using IPTp

Table 2
Health information and obstetric history of pregnant women receiving antenatal care at Korle-Bu Teaching Hospital, Accra, Ghana,
June–August 2009*
Variable

Gestation
Second trimester
Third trimester
Gravidae
Primigravidae
Secundigravidae
Gravidae ≥ 3
Parity
0
1
2
≥3
Sickle cell status
Positive
Negative
Not known
G6PD
Normal
Abnormal
Not known
HIV status
Positive
Negative
Not known
Helminth infection
Roundworm
Malaria co-infection
None

IPTp-SP
users (n = 202)

Non-IPTp-SP
users (n = 161)

10 (5.0%)
192 (95.0%)

11 (6.8%)
150 (93.2%)

0.591

23 (11.4%)
59 (29.2%)
120 (59.4%)

27 (16.8%)
47 (29.2%)
87 (54.0%)

0.311

34 (16.8%)
67 (33.2%)
71 (35.1%)
30 (14.9%)

28 (17.4%)
58 (36.0%)
57 (35.4%)
18 (11.2%)

0.767

16 (7.9%)
184 (91.1%)
2 (1.0%)

12 (7.5%)
144 (89.4%)
5 (3.1%)

0.344

191 (94.5%)
7 (3.5%)
4 (2.0%)

147 (91.3%)
8 (5.0%)
6 (3.7%)

0.453

7 (3.4%)
187 (92.6%)
8 (4.0%)

6 (3.7%)
147 (91.3%)
8 (5.0%)

0.887

8 (4.0%)
–
194 (96.0%)

4 (2.5%)
5 (3.1%)
152 (94.4%)

< 0.032

P

* IPTp-SP = intermittent preventive treatment with sulfadoxine-pyrimethamine; G6PD =
glucose-6-phosphate dehydrogenase; HIV, human immunodeficiency virus. Pearson chisquare test adjusting for the Yates correction for continuity where appropriate were used to
compare for statistical differences among the pregnant women. For instances in which there
were too few persons per cell for the Pearson chi-square test to be used, Fisher exact test was
used to compare discrete outcomes. Statistical significance was set at P ≤ 0.05.
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Table 3
Malaria prevention methods used and effect of intermittent preventive treatment with sulfadoxine-pyrimethamine on malaria in pregnant women
receiving antenatal care at Korle-Bu Teaching Hospital, Accra, Ghana, June–August 2009*
IPTp-SP users (n = 202)
Variable

ITN use

Yes
No
Yes
No

IRS use

Non-IPTp-SP users (n = 161)

Malaria+

Malaria–

Malaria+

Malaria–

P

4 (2.0%)
27 (13.4%)
18 (8.9%)
13 (6.4%)

10 (5.0%)
161 (79.7%)
98 (48.5%)
75 (37.1%)

4 (2.5%)
68 (42.2%)
39 (24.2%)
33 (20.5%)

5 (3.1%)
84 (52.2%)
53 (32.9%)
36 (22.4%)

0.657
< 0.0001
< 0.0001
< 0.0001

* IPTp-SP = intermittent preventive treatment with sulfadoxine-pyrimethamine; ITN = insecticide-treated net; IRS = indoor residual spraying. Pearson chi-square test adjusting for the Yates
correction for continuity where appropriate were used to compare for statistical differences among the pregnant women. For instances in which there were too few persons per cell for the Pearson
chi-square test to be used, Fisher exact test was used to compare discrete outcomes. Statistical significance was set at P ≤ 0.05.

was significantly higher (58.4%, 94 of 161) than in women using
IPTp (22.8%, 46 of 202) (P < 0.001) (Table 5). The proportion
of severely anemic women was also significantly higher among
women not using IPTp (12.4%, 20 of 161) than among women
using IPTp (3.5%, 7 of 202) (P < 0.001) (Table 5).
When the possible confounding effect of age, marital status, gestation, parity, food supplement, and other variables was
controlled by using multivariate logistic regression, the effect
of IPTp in prevention of anemia and severe anemia remained
statistically significant (P < 0.001). Malaria infection and IPTp
were the only variables shown to be statistically significant as
explanatory variables for anemia and severe anemia in pregnancy. In addition, sickle cell status was also statistically significant as an explanatory variable for anemia in pregnancy (OR =
2.35, 95% CI = 1.12–6.01, P < 0.035). The chance of anemia
among pregnant women using IPTp was 20% that of women
not using IPTp (OR = 0.20, 95% CI = 0.12–0.34, P < 0.0001),
and the chance of severe anemia was 17% that of women
not using IPTp (OR = 0.17, 95% CI = 0.06–0.49, P < 0.0001).
Interestingly, the chances of anemia and severe anemia among
pregnant women with malaria infection were approximately
five-fold (OR = 5.08, 95% CI = 2.72–9.49, P < 0.0001) and
Table 4
Logistic regression analyses of contributory factors for malaria among
pregnant women receiving antenatal care at Korle-Bu Teaching
Hospital, Accra, Ghana, June–August 2009*
Variable

Odds ratio

95% CI

P

Age
Marital status
Gestation
Parity
Primigravidae
Secundigravidae
Education
Employment grade
Family size
IPTp-SP Use
IPTp-SP × primigravidae
IPTp-SP × secundigravidae
Sickle cell positive
Abnormal G6PD
HIV positive
ITN use
IRS use

1.00
2.03
0.52
1.08
1.31
1.08
0.48
2.04
0.93
0.18
3.37
1.52
0.72
2.64
1.24
1.38
0.93

0.94–1.07
0.41–10.11
0.19–1.41
0.68–1.72
0.38–4.54
0.47–2.48
0.28–0.81
0.42–9.91
0.37–2.30
0.08–0.37
0.79–14.83
0.46–4.98
0.28–1.88
0.98–7.15
0.48–3.20
0.49–3.84
0.54–1.59

0.917
0.389
0.198
0.752
0.676
0.865
0.006
0.377
0.867
< 0.0001
0.102
0.489
0.507
0.056
0.655
0.544
0.780

* CI = confidence interval; IPTp-SP = intermittent preventive treatment with sulfadoxinepyrimethamine; G6PD = glucose-6-phosphate dehydrogenase; HIV = human immunodeficiency virus; ITN = insecticide-treated net; IRS = indoor residual spraying. The odds ratio
and 95% CI were obtained with logistic regression in multivariate analyses adjusted for age,
parity, and other variables in the study. Statistical significance was set at P ≤ 0.05. Model I was
used for the logistic regression analysis. In the logistic regression model, age, parity, marital
status, and family size were treated as covariate and other variables were treated as categorical variables. The reference for primigravidae and secundigravidae was gravidae ≥ 3, that for
IPTp-SP was pregnant women not using IPTp, and that for education was women with no
education. Values in bold are statistically significant.

10-fold (OR = 9.92, 95% CI = 3.58–27.48, P < 0.0001) higher,
respectively, compared with those in women with no malaria
infection (Table 6).
DISCUSSION
Malaria is the leading cause of illness and death in Ghana
and it impacts negatively on different demographic and
socio-economic groups.25 It contributes to the relatively high
maternal mortality in the country, which accounts for 11% of
mortality in pregnant women.25 Although anemia remains a
major challenge in sub-Sahara Africa, malaria is an important
contributor to maternal and perinatal morbidity and mortality in these countries.10 The WHO currently recommends that
each pregnant woman should receive IPTp-SP at each ANC
visit after quickening, which in practice leads to two or three
doses during the course of the pregnancy.2 This recommendation is based on reports of beneficial effects of IPTp-SP in preventing maternal malaria and improving pregnancy outcome
in studies conducted in Africa.10,15,17,18,27,28 This policy has been
adopted by most countries in Africa, but implementation has
been suboptimal.29 Furthermore, the spread of SP-resistant
P. falciparum reinforces the importance of investigating the
ongoing effectiveness of IPTp-SP.19,20,23,30,31 This study assessed

Table 5
Anemia prevention knowledge and effect of intermittent preventive
treatment with sulfadoxine-pyrimethamine on anemia in pregnant
women receiving antenatal care at Korle-Bu Teaching Hospital,
Accra, Ghana, June–August 2009*
Variable

IPTp-SP
users (n = 202)

Hemoglobin, g/dL
Mean ± SD
11.6 ± 1.6
Anemia (< 11.0)
46 (22.8%)
Severe anemia (< 7.0)
7 (3.5%)
≥ 11.0
149 (73.7%)
Anemia prevention knowledge
Food supplement
49 (24.2%)
Adequate nutrient
148 (73.3%)
None
5 (2.5%)
Food supplement
Yes
168 (83.2%)
No
34 (16.8%)
Food allergies
Yes
4 (2.0%)
No
198 (98.0%)

Non-IPTp-SP
users (n = 161)

P

9.7 ± 1.8
94 (58.4%)
20 (12.4%)
47 (29.2%)

< 0.001
< 0.001
< 0.001
< 0.001

38 (23.6%)
109 (67.7%)
14 (8.7%)

0.030

134 (83.2%)
27 (16.8%)

0.900

3 (1.9%)
158 (98.1%)

0.761

* IPTp-SP, intermittent preventive treatment with sulfadoxine-pyrimethamine; SD = standard deviation. Pearson chi-square test adjusting for the Yates correction for continuity where
appropriate were used to compare for statistical differences among the pregnant women. For
instances in which there were too few persons per cell for the Pearson chi-square test to be used,
Fisher exact test was used to compare discrete outcomes. Differences between group means
were assessed by using analysis of variance and statistical significance was set at P ≤ 0.05.

16

WILSON AND OTHERS

Figure 1. Hemoglobin levels among intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)
and non IPTp-SP groups of pregnant women receiving antenatal care
at Korle-Bu Teaching Hospital, Accra, Ghana. Differences between
group means and median were assessed by using analysis of variance.
Statistical significance was set at P ≤ 0.05. Box plots represent median
of hemoglobin levels (g/dL) and 25th and 75th percentiles. Outliers
are shown as points outside the 10th and 90th percentile bars. Dotted
line represents the mean and * denotes P < 0.05.

whether pregnant women attending the ANC at KBTH who
had used IPTp-SP had low prevalence of malaria and anemia or severe anemia compared with those who had not used
IPTp-SP.
Results showed that pregnant women who used IPTp-SP
had a statistically lower prevalence or rate of malaria, anemia, and severe anemia than those who did not use IPTp-SP.

Only 15% of the women using IPTp were positive for malaria
infection compared with approximately 45% of the women
not using IPTp. The lower prevalence may be partly caused
by the frequency of ITN and IRS use among the participants.
However, controlling the effect of the variables in the study
by using logistic regression analysis, ITN and IRS use did not
influence the outcome of malaria infection. The ITNs represent a powerful tool for preventing malaria transmitted by
mosquitoes residing indoors at night.32,33 However, recent evidence suggests that some mosquito populations avoid contact
with ITNs by either feeding predominately outdoors or in the
early part of the evening when individuals are not under the
nets.32,34,35 Such behavioral changes may reduce the level of
personal protection conferred by ITNs.34,35
Although ITNs may be ineffective against outdoor-biting
mosquitoes,35,36 ITNs continue to play an integral part of
malaria vector control.32 Personal protective measures such
as spatial repellents should be considered as a supplement
to ITNs to protect against indoor (outside nets) and outdoor bites in the morning or early evening.32,37 The ITNs have
been shown to be effective in the control of malaria in pregnant women.38,39 However, their use among pregnant women
in the study was low (6.3%). This finding may be caused by
lack of access or compliance, the cost of acquiring ITNs, or by
the fact that this cohort of participants prefer IRS over ITNs.
Furthermore, a higher proportion of non-IPTp-SP users not
using ITNs (42.2% versus 13.4%) or IRS (20.5% versus 6.4%)
had malaria when compared with IPTp-SP users (P < 0.0001),
which suggests that IPTp-SP is effective in reducing the prevalence of malaria.
Although the prevalence of malaria among IPTp users
could be caused by re-infection between doses of SP, drug
resistance may have played a part in this observation
because high levels of resistance to SP has been reported.40–42
Furthermore, a high prevalence rate (73%) of the gene

Table 6
Logistic regression analyses of contributory factors for anemia among the pregnant women receiving antenatal care at Korle-Bu Teaching Hospital,
Accra, Ghana, June–August 2009*
Anemia

Severe anemia

Variables

Odds ratio

95% CI

P

Odds ratio

95% CI

P

Age
Marital status
Gestation
Parity
Primigravidae
Secundigravidae
Education
Employment grade
Family size
Sickle cell positive
HIV positive
Abnormal G6PD
Helminth infection
Malaria infection
IPTp-SP use
Food supplement
ITN use
IRS use
Anemia prevention knowledge

0.96
1.82
1.60
1.12
1.15
1.31
0.97
0.95
0.92
2.35
0.60
0.38
1.06
5.08
0.20
1.00
0.99
1.17
0.70

0.90–1.03
0.41–7.98
0.51–5.00
0.65–1.94
0.34–3.75
0.63−2.73
0.66–1.43
0.66–1.37
0.65–1.30
1.12–6.01
0.22–1.66
0.10–1.39
0.28–4.03
2.72–9.49
0.12–0.34
0.50–2.00
0.33–2.97
0.67–2.05
0.21–2.35

0.240
0.420
0.423
0.673
0.816
0.465
0.881
0.789
0.624
0.035
0.324
0.142
0.935
< 0.0001
< 0.0001
0.996
0.576
0.576
0.557

0.99
4.53
2.76
1.07
7.02
2.46
0.84
1.02
0.98
1.70
0.61
1.87
1.37
9.92
0.17
0.68
0.38
0.54
1.70

0.88–1.11
0.29–69.21
0.26–29.63
0.42–2.71
0.99–49.72
0.61–9.92
0.40–1.79
0.52–2.00
0.64–1.49
0.29–9.49
0.09–4.14
0.37–9.62
0.17–11.40
3.58–27.48
0.06–0.49
0.21–2.21
0.04–3.94
0.20–1.46
0.10–28.36

0.991
0.277
0.402
0.887
0.051
0.205
0.659
0.947
0.926
0.570
0.615
0.452
0.769
< 0.0001
0.001
0.523
0.419
0.223
0.711

* CI = confidence interval; HIV = human immunodeficiency virus; G6PD = glucose-6-phosphate dehydrogenase; IPTp-SP, intermittent preventive treatment with sulfadoxine-pyrimethamine;
ITN, insecticide-treated net; IRS = indoor residual spraying. The odds ratio and 95% CI were obtained with logistic regression in multivariate analyses adjusted for age, parity, and other variables
in the study. Statistical significance was set at P ≤ 0.05. Model I was used for the logistic regression analysis. In the logistic regression model, age, parity, marital status, and family size were treated
as covariate and other variables were treated as categorical variables. The reference for primigravidae and secundigravidae was gravidae ≥ 3, that for IPTp-SP was pregnant women not using IPTp,
and that for education was women with no education. Values in bold are statistically significant.
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encoding the dihydrofolate reductase triple mutation among
P. falciparum that confers resistance to SP has been reported
in pregnant women in Ghana.22 In addition, SP treatment failure has been observed in approximately 30% of pregnant
women in Ghana.21 Nevertheless, supplementation with high
dosages of folate during pregnancy may compromise the efficacy of IPTp-SP.29 Sulfadoxine-pyrimethamine works through
its inhibition of folate synthesis, and studies have linked high
host folate levels with reduced SP efficacy.43 Because of folate
synthesis inhibition by SP, folate supplementation has been
recommended for all pregnant women in Africa to reduce the
risk of fetal neural tube defects.29 In addition, because most
(83.2%) of the women in this study used food supplements
containing folate (Table 5), the efficacy of IPTp-SP may be
reduced and may result in vulnerability to malaria infection.
However, the result indicates that the deleterious effects of
malaria during pregnancy can be substantially reduced using
IPTp-SP in pregnant women.
Prevalence of malaria infections is high in primigravidae
from malaria-endemic communities with different levels of
transmission.44 Additionally, the presence of malaria parasites in the peripheral blood of clinically symptomatic pregnant women is an indication of on-going placental infection.45
Other studies have observed a strong correlation between
placental infection and peripheral infection at the beginning
and at the end of pregnancy.46–48 These studies suggest that
peripheral parasitemia at any stage of the pregnancy was significantly correlated with placental infection at delivery.46–48
Several studies have shown that peripheral and placental
parasitemia decrease with increasing parity among pregnant
women.44,49 It has been observed that pregnant women, especially primigravidae and secundigravidae, are more susceptible to malaria infections.46 In a community-based study in
Ghana, Ofori and others44 reported that malaria infections
were most common among primigravidae and secundigravidae, suggesting that any measure to protect pregnant women
against malaria should be prioritized to first and second pregnancies.44 A common explanation is that pregnancy is associated with a decrease in immunity, which is more pronounced
in primigravidae than in multigravidae.46 The decreasing susceptibility to pregnancy-associated malaria with increasing
parity is reflected in the acquisition of antibodies specific for
parasite variant antigens expressed on the surface of infected
erythrocytes.46,50 Although there is increasing evidence that
prevalence of malaria infections is parity-related and primigravidae was the most at-risk group during pregnancy,44,51–55 in
the current study, parity or primigravidae did not show any
association with malaria infection (Table 4). This finding may
have been caused by the failure of small sample size to show
any association between parity or gravidity and malaria infection. Interestingly, with the exception of IPTp-SP use, education was a factor that showed an association with malaria
(Table 4). This finding indicate that education may influence health-seeking behavior; educated women may be more
proactive in taking measures to prevent malaria than uneducated women. However, in this study, use of malaria prevention methods such as ITNs or indoor spraying did not show
any association with malaria infection. Nevertheless, several
studies have shown ITNs to reduce malaria morbidity and
mortality.23,38,56,57
Anemia is a well-recognized consequence of malaria.
Although maternal anemia is multi-factorial, malaria is known
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to contribute significantly to its occurrence in pregnancy.55,59–61
The beneficial effect of IPTp-SP on reduction of the prevalence of maternal anemia will improve pregnancy outcome.
The lower rate of anemia and severe anemia observed among
pregnant women using IPTp (Table 5) was consistent with
the findings reported earlier in Malawi, where the use of SP
was associated with a higher maternal hemoglobin level.28 The
results of our study were consistent with studies in Kenya,17
Nigeria,10 and other parts of Africa, which demonstrates that
IPTp is effective in reducing the risk of anemia among pregnant women.14,15,62–64 However, these studies compared IPTp-SP
with weekly chloroquine prophylaxis10,14,64 or placebo and case
management,15,17,62–64 and our approach was a cross-sectional
study that compared IPTp-SP users with non-users. In addition, amid growing concerns of chloroquine resistance and the
approximately 11% of pregnant women adhering to the policy
of using chloroquine to prevent malaria in pregnancy, Ghana
adopted IPTp-SP as the only nationally recommended drug
for management of malaria in pregnancy in 2003.25 Despite this
limitation, IPTp-SP was highly effective in reducing maternal
malaria-associated anemia in pregnancy (Table 5).
The contribution of malaria infection to anemia in pregnant women is one of the reasons for preventing malaria
during pregnancy.65 Although other conditions such as helminth infections, HIV, and sickle cell disease may contribute to
the incidence of anemia among populations in sub-Saharan
Africa, controlling for these confounding effects in our study
did not influence the outcome of anemia among the participants. However, malaria was the only contributory factor for
anemia and severe anemia among pregnant women (Table 6).
The impact of malaria infections on anemia might vary with
different malaria endemicity levels and therefore with the
level of pre-pregnancy–acquired malaria immunity.66 Malariaassociated anemia may be caused by an increase in the density
of parasitemia rather than mere presence of parasite infection.67 However, the current study did not measure parasite
density in the peripheral blood to determine its association
with anemia. Furthermore, parasite density measured from
peripheral blood does not reflect degree of sequestration in
placenta. Evidence that IPTp-SP reduces maternal malariaassociated anemia has been shown in several studies in subSaharan Africa10,15,17,27. Nevertheless, our study indicates that
IPTp-SP use was the only factor that provides protection
against anemia or severe anemia among the pregnant women
(Table 6).
The results from this study demonstrate the effectiveness of
IPTp-SP in reducing the prevalence of malaria and the development of malaria-related anemia or severe anemia in pregnancy in a malaria-endemic area. These findings provide an
evidence-based template on which policymakers and health
workers may develop interventions to reduce maternal mortality caused by malaria and malaria-associated anemia in
pregnancy. The simple regimen of SP and its relatively low
incidence of side effects make it highly acceptable to pregnant
women and health workers. In addition, studies from Africa
have reported high prevalence rates of congenital malaria
ranging from 4.9% to 46.7%.68–77 Furthermore, a recent study
reported that mothers using anti-malarial prophylaxis during pregnancy have fewer babies with congenital malaria
compared with mothers who are not using anti-malarial
prophylaxis.78 This finding suggests that the use of SP may
not only prevent maternal morbidity and mortality caused by
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malaria and malaria-associated anemia in pregnancy but also
prevent gestational and placental malaria, thereby reducing
the incidence of congenital malaria. Interestingly, a previous
study in Ghana reported approximately 36% of asymptomatic malaria (presence of malaria parasite without symptoms) among pregnant women.79 Similarly, up to 82.4% of
asymptomatic infection has been reported in other parts of
Africa,55,80 suggesting that most malaria infection among pregnant women go undiagnosed. Thus, the SP regimen will be
useful in decreasing the prevalence of asymptomatic malaria
among pregnant women in malaria-endemic areas. Although
there is a small risk of adverse reactions to sulfa-containing
drugs,81,82 in malaria-endemic area with associated high level
of malaria attributable anemia in pregnancy with its implications for negative pregnancy outcomes, the benefits of this
regimen far outweighs this potential risk.10 Much work still
needs to be done to improve coverage of SP so that all pregnant women receive at least two doses of IPTp. Furthermore,
strategies need to be developed to distribute IPTp-SP to the
various regions and rural communities to reach pregnant
women who do not attend ANC.
The main limitation of this study was the lack of measurements of pregnancy outcomes such as LBW and placental parasitemia, which are sensitive indicators of malaria in pregnancy.
The study was cross-sectional and the data did not include follow-up. Measurement of these parameters could have given
insight into the effect of the IPTp-SP on the prevalence of
LBW and placenta parasitemia at KBTH. However, several
studies have indicated that IPTp-SP is efficient in reducing placental parasitemia and prevention of LBW.27,28,59,83–85 Although
the study recruited more than 300 women, these women only
account for less than 10% of the total number of women
attending ANC annually. In addition, facility-based surveys as
tools to evaluate changing malaria epidemiology have been
critiqued in a recent report.86 Because the study used hospital-based convenience sampling, we cannot claim that these
results are representative of changing malaria epidemiology in
the whole community. However, by using one facility and the
same approach to assess all variables throughout the study,87
we believe that the study provides insight into malaria control
and prevention.
We recommend that further studies be conducted to assess
the efficacy of SP in pregnancy in the clinical setting where
LBW and placental parasitemia is measured and to evaluate other drug combinations for malaria prevention in pregnancy. Additionally, there is a need to evaluate and monitor
the effectiveness of SP for IPTp because resistance to this
drug is increasing. A search for drugs that are more efficacious or a combination of such is therefore necessary. Because
folate supplementation has been recommended for all pregnant women in Africa to reduce the risk of fetal neural tube
defects, its influence on the efficacy of SP need to be evaluated
because high doses inhibit SP efficacy. In addition, this was a
clinic-based study, a community-based study would have captured IPTp use and knowledge on malaria and anemia prevention among women who have not been exposed to health
facilities, especially antenatal clinics.
Importantly, use of IPTp-SP is a useful and practical strategy to reduce risk of malaria and malaria-related anemia
and asymptomatic malaria among pregnant women living
in malaria-endemic areas such as Ghana. This goal may be
attained by increasing the proportion of pregnant women

receiving IPTp-SP through focused antenatal care services
and information campaigns. In the present study, women with
higher educational status were more likely to take preventive measures against malaria compared with less educated
women. This finding means that health education programs
for pregnant women should be intensified among women with
low educational status.
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